The Use of Memantine for Prevention of Alzheimer's Disease

Eligibility Criteria

• 1. Be between the age of 50 and 65 years at time of informed consent.
• 2. Have a positive family history for dementia (minimum of 1 first degree relative).
• 3. Previously known or documented heterozygote or homozygote ApoE ε4 allele.
• 4. Be able to read and write and must have adequate hearing and visual acuity to complete the psychometric tests.
• 5. Be otherwise healthy for their age group or medically stable with or without medication on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening or at baseline.
• 6. Have Montreal Cognitive Assessment (MOCA) score of 27 or above.
• 7. Have a creatinine clearance (CrCl), estimated using the Cockcroft-Gault formula, greater or equal to 30 mL/minute.
• 1. A current clinical condition or requires a medication that raises the pH of their urine.
• 2. Severe renal or hepatic impairment.
• 3. Any other abnormality that could cause a possible cognitive deficit (including, but not limited to, vascular encephalopathy or large strokes).
• 4. Contraindications for MRI (e.g., prostheses, implants, claustrophobia, pacemaker) or PET imaging.
• 5. Neurodegenerative disorder known to cause neurocognitive decline
• 6. Relevant history of or current neurological disease other than preclinical AD, which may make interpretation of possible new neurological signs or symptoms difficult.
• 7. Clinically significant and active pulmonary, gastrointestinal, renal, hepatic, endocrine, or cardiovascular system disease
• 8. Ongoing cancer treatment
• 9. Clinically significant and active psychiatric disorder
• 10. Use of an investigational medical device within 3 months before the planned start of study.
• 11. Current participation in an interventional study with an investigational drug component.
• 12. Major surgery (e.g., requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgery, or has major surgery planned during the time the subject is expected to participate in the study.
• 13. Requires treatment with an AChE inhibitor or any of the following: acetazolamide, methazolamide, amantadine, ketamine, dextromethorphan.